103362-70-5

Basic information

• Product Name: Propanedioic acid, methyl-, monoethyl ester, potassium salt
• CAS NO: 103362-70-5
• Molecular Formula: C6H10O4.K
• Molecular Weight: 184.233
• Mol File: 103362-70-5.mol

Chemical Properties

• CAS DataBase Reference: Propanedioic acid, methyl-, monoethyl ester, potassium salt(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, methyl-, monoethyl ester, potassium salt(103362-70-5)
• EPA Substance Registry System: Propanedioic acid, methyl-, monoethyl ester, potassium salt(103362-70-5)

Safety Data

• Hazardous Substances Data: 103362-70-5(Hazardous Substances Data)

Upstream product

• 609-08-5 Diethyl methylmalonate 
• 6065-52-7 2-Methylpropanedioic Acid Ethyl Methyl Ester 
• 105-53-3 diethyl malonate 

Downstream Products

• 2985-33-3 monoethyl methylmalonate 
• 24161-56-6 ethyl 2-nitrophenyl methylmalonate 
• 29304-43-6 ethyl 2-methyl-3-oxo-5-phenylpentanoate 
• 195883-17-1 2-(4-tert-Butyl-benzylsulfanylcarbonyl)-propionic acid ethyl ester 
• 359828-74-3 ethyl 4-(2,6-difluorophenyl)-2,4-dimethyl-3-oxobutanoate 
• 2867-62-1 ethyl 2-methyl-3-oxo-4-phenylbutanoate 
• 221121-47-7 ethyl 2-methyl-3-oxo-4-(2,6-dichlorophenyl)butanoate 
• 221121-43-3 4-(4-fluoro-phenyl)-2-methyl-3-oxo-butyric acid ethyl ester 
• 948859-49-2 ethyl 4-acetoxy-4-(4-fluorophenyl)-2-methyl-3-oxobutanoate 
• 958237-59-7 4-(2,6-dichlorophenyl)-2-methyl-3-oxo-pentanoic acid ethyl ester 
• 958237-61-1 4-(2,6-dichlorophenyl)-2-methyl-3-oxo-hexanoic acid ethyl ester 
• 776296-99-2 ethyl 2-methyl-3-oxo-4,4-diphenylbutanoate 
• 944826-07-7 ethyl 4-(3-bromophenyl)-2-methyl-3-oxo-butyrate 
• 2510-99-8 ethyl 2-phenylpropanoate 

Relevant articles and documents

Design, synthesis and anti-HIV evaluation of 5-alkyl- 6-(benzo[d][1,3]dioxol-5-alkyl)-2-mercaptopyrimidin-4(3H)-ones as potent HIV-1 NNRTIs

In order to discover and develop the new HIV-1 NNRTIs, a series of 5-alkyl-6-(benzo[d][1,3]dioxol-5-ylalkyl)-2-mercaptopyrimidin-4(3H)-ones was synthesized and screened for their in vitro cytotoxicity against HIV-1. Most of the compounds we synthetized sh

Efficient Decarboxylative/Defluorinative Alkylation for the Synthesis of gem-Difluoroalkenes through an SN2’-Type Route

An efficient decarboxylative/defluorinative alkylation for synthesizing gem-difluoroalkenes is described, providing a general method for installation of the challenging alkyl fragments containing α-electron-withdrawing groups into α-trifluoromethyl alkenes. Mechanistic studies suggest that this process involves an SN2′-type synthetic route in the absence of transition-metal catalysts or photocatalysis. Moreover, this protocol can easily be scaled up, and successfully applied to the modification of biologically active molecules, thus complementing methodologies that give access to structurally versatile gem-difluoroalkenes.

SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.

Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

In continuation of our efforts toward the discovery of potent HIV-1 NNRTIs with diverse structures, a series of novel S-DACO analogues of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenyl-ethylsulfanyl)pyrimidin-4(3H)-ones were designed, synthesized and evaluated for their antiviral activities in MT-4 cells. Most of these new compounds showed moderate to good activities against wild type HIV-1 with IC50 values ranging from 7.55 μmol/L to 0.018 μmol/L. Among them, compound 5c was identified as the most promising inhibitor against HIV-1 replication with an IC50 = 0.018 μmol/L, CC50 = 194 μmol/L, and SI = 12791, which was much more potent than the reference drugs NVP and DLV and comparable to AZT and EFV. In addition, 5c also exhibited improved activity against double mutant HIV-1 strain RES056 compared to that of the reference drugs NVP/DLV and DB02. The preliminary structure-activity relationship (SAR) and molecular modeling studies were also discussed, which provides some useful indications for guiding the further rational design of new S-DACO analogues.

Dynamic Kinetic Resolution of I-Substituted Cyclic β-Ketoesters via Asymmetric Hydrogenation: Constructing Chiral Cyclic β-Hydroxyesters with Three Contiguous Stereocenters

An efficient asymmetric hydrogenation of racemic I-substituted cyclic β-ketoesters via dynamic kinetic resolution to provide chiral cyclic β-hydroxy esters with three contiguous stereocenters is reported. Using a chiral spiro iridium catalyst (R)-5 (Ir-SpiroSAP), a series of racemic I-Aryl/alkyl substituted cyclic β-ketoesters were hydrogenated to the corresponding chiral cyclic β-hydroxy esters in high yields (84-97%) with good to excellent enantioselectivities (69->99% ee) and cis,cis-selectivities (up to >99:1).

6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase

3-Hydroxypyrimidine-2,4-dione (HPD) represents a versatile chemical core in the design of inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated RNase H and integrase strand transfer (INST). We report herein the design, synthesis and biological evaluation of an HPD subtype (4) featuring a cyclohexylmethyl group at the C-6 position. Antiviral testing showed that most analogues of 4 inhibited HIV-1 in the low nanomolar to submicromolar range, without cytotoxicity at concentrations up to 100?μM. Biochemically, these analogues dually inhibited both the polymerase (pol) and the RNase H functions of RT, but not INST. Co-crystal structure of 4a with RT revealed a nonnucleoside RT inhibitor (NNRTI) binding mode. Interestingly, chemotype 11, the synthetic precursor of 4 lacking the 3-OH group, did not inhibit RNase H while potently inhibiting pol. By virtue of the potent antiviral activity and biochemical RNase H inhibition, HPD subtype 4 could provide a viable platform for eventually achieving potent and selective RNase H inhibition through further medicinal chemistry.

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family

Preventing HIV transmission by the use of a vaginal microbicide is a topic of considerable interest in the fight against AIDS. Both a potent anti-HIV agent and an efficient formulation are required to develop a successful microbicide. In this regard, molecules able to inhibit the HIV replication before the integration of the viral DNA into the genetic material of the host cells, such as entry inhibitors or reverse transcriptase inhibitors (RTIs), are ideal candidates for prevention purpose. Among RTIs, S- and N-dihydroalkyloxybenzyloxopyrimidines (S-DABOs and N-DABOs) are interesting compounds active at nanomolar concentration against wild type of RT and with a very interesting activity against RT mutations. Herein, novel N-DABOs were synthesized and tested as anti-HIV agents. Furthermore, their mode of binding was studied by molecular modeling. At the same time, a vaginal microbicide gel formulation was developed and tested for one of the most promising candidates.

Pd-catalyzed decarboxylative cross-couplings of potassium malonate monoesters with aryl halides

An efficient catalytic protocol for Pd-catalyzed decarboxylative cross-coupling of potassium malonate monoesters and derivatives with aryl bromides and chlorides are described. Because of its broad applicability, this new catalytic system provides an alternative method for the preparation of diverse aryl acetic acids and derivatives.

Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

A novel series of 2-arylcarbonylmethylthio-6-arylmethylpyrimidin-4(3H)-ones have been synthesized and evaluated for in vitro anti-HIV activities in MT-4 cells. Most of these new compounds showed moderate to potent activities against wild-type HIV-1 with a